Nordic Nanovector ASA
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It develops Ra224, an isotope of radium; Pb-212, a radioactive isotope of lead; and Th-228, a radioactive isotope of thorium. The company was incorporated in 2009 and is headquartered in Oslo, Norway.
Nordic Nanovector ASA (8NN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2022: -0.430x
Based on the latest financial reports, Nordic Nanovector ASA (8NN) has a cash flow conversion efficiency ratio of -0.430x as of June 2022.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-78.41 Million) by net assets (€182.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Nordic Nanovector ASA - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Nordic Nanovector ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Nordic Nanovector ASA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nordic Nanovector ASA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lee Chi Enterprises Co Ltd
TW:1517
|
0.004x |
|
GaeaSoft Corp
KQ:051160
|
0.021x |
|
DY Corporation
KO:013570
|
0.007x |
|
New Horizon Aircraft Ltd
NASDAQ:HOVR
|
-0.180x |
|
Abm Investama Tbk
JK:ABMM
|
0.038x |
|
APB Apranga
MU:WHX
|
0.210x |
|
Shenzhen Zhongzhuang Construction Group Co Ltd
SHE:002822
|
-0.006x |
|
PADAUK Technology Co. Ltd
TWO:6716
|
0.030x |
Annual Cash Flow Conversion Efficiency for Nordic Nanovector ASA (2016–2024)
The table below shows the annual cash flow conversion efficiency of Nordic Nanovector ASA from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €337.14 Million | €-23.98 Million | -0.071x | +69.82% |
| 2023-12-31 | €271.93 Million | €-64.09 Million | -0.236x | +96.32% |
| 2022-12-31 | €63.84 Million | €-409.08 Million | -6.408x | -123.17% |
| 2021-12-31 | €140.52 Million | €-403.46 Million | -2.871x | -28.83% |
| 2020-12-31 | €178.67 Million | €-398.21 Million | -2.229x | -110.60% |
| 2019-12-31 | €388.01 Million | €-410.62 Million | -1.058x | -17.68% |
| 2018-12-31 | €363.19 Million | €-326.63 Million | -0.899x | -145.04% |
| 2017-12-31 | €679.61 Million | €-249.43 Million | -0.367x | -70.80% |
| 2016-12-31 | €949.29 Million | €-203.98 Million | -0.215x | -- |